BJMO - volume 17, issue 4, june 2023
A. Verbiest MD, PhD, M. Baldewijns MD, PhD, B. Beuselinck MD, PhD, P. Debruyne MD, PhD, C. Gennigens MD, PhD, G. Pelgrims MD, T. Roumeguère MD, PhD, E. Seront MD, PhD, N. Sundahl MD, PhD, S. Rottey MD, PhD
The management of renal cell carcinoma is evolving rapidly. Here, the BSMO expert panel discusses recent advances focusing on systemic therapies, and provides guidelines adapted to the Belgian context.
(BELG J MED ONCOL 2023;17(4):118–27)Read more
BJMO - volume 16, issue 6, october 2022
E. Seront MD, PhD, V. Dekeuleneer MD, A. van Damme MD, PhD, L. Boon MD, PhD, M. Vikkula MD, PhD
Vascular malformations are rare diseases that result from anomalies in the angiogenesis process. They are subdivided into capillary, lymphatic, venous, arteriovenous, and mixed malformations, according to the type of affected vessels. Until a few years ago, therapeutic options were limited to sclerotherapy and/or surgery, but these treatments are rarely curative or not feasible. Most vascular malformations are caused by inherited or somatic mutations in various genes. These mutations are similar to oncogenic mutations detected in cancer, leading to hyperactivity of important signalling pathways, including MAPK and PI3K/AKT/mTOR cascades. This article highlights the role of targeted molecular inhibitors as therapies for vascular anomalies via repurposing of anticancer drugs.
(BELG J MED ONCOL 2022;16(6):293–99)Read more
BJMO - volume 14, issue 7, november 2020
E. Seront MD, PhD, F. Jamar MD, PhD, K. Goffin MD, PhD, I. Billiet MD, V. Vanhaudenarde MD, A. Van den Eeckhaut MD, Sofie Willems MD, P. De Wil MD, A. Sacré MD, N. Mahy MD, R. Bierlaire , J. Deferme , D. Schrijvers MD, PhD
BELFIGO is a national retrospective chart review that aimed to assess the sequencing and application of radium-223 (Ra-223) within routine clinical practice, and evaluate the use of Ra-223 in monotherapy. The collection of data was primarily used to describe the proportion of Belgian metastatic Castration Resistant Prostate Cancer patients receiving one-four versus five-six Ra-223 injections, and the potentially associated patient characteristics. In total, 164 patients from eleven centres in Belgium were included and analysed in this study. Hundred-thirteen patients (69%) completed five-six injections of Ra-223. There was a trend that patients with a lower Eastern Cooperative Oncology Group Performance Status score, lower extent of disease on bone scan, alkaline phosphatase at baseline < 140 U/L and lactate dehydrogenase at baseline <250 U/L showed a higher chance of completing the six cycles of Ra-223. Median overall survival was estimated at 6.9 months for the patients having received one-four injections and 23.8 months for patients who completed five-six injections of Ra-223. More than 70% of patients received at least one treatment line after Ra-223, mainly enzalutamide, docetaxel or abiraterone acetate. These results show that the life-prolonging targeted alpha-therapy Ra-223 does not preclude the start of subsequent lines of treatment and that its use in an earlier line results, in a higher probability of reaching five-six doses. Patients with less advanced disease are more likely to complete five-six injections and tend to have a higher median overall survival.
(BELG J MED ONCOL 2020;14(7):347-54)Read more
BJMO - volume 13, issue 6, october 2019
P. Ost MD, PhD, D. Schrijvers MD, PhD, L. Duck MD, M. Gizzi MD, K. Goffin MD, PhD, S. Joniau MD, PhD, S. Rottey MD, PhD, T. Roumeguère MD, PhD, E. Seront MD, PhD, N. Withofs MD, PhD, B. Tombal MD, PhD
The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has changed dramatically with the approval of a variety of therapeutic agents including abiraterone acetate, cabazitaxel, docetaxel, enzalutamide and radium-223 dichloride and the introduction of docetaxel and abiraterone acetate in combination with androgen deprivation therapy in newly diagnosed metastatic prostate cancer. Evidence on the optimal sequence of these therapies is scarce. In practice, the most appropriate treatment (sequence) depends on patient and disease characteristics. This article summarises the recommendations of a multidisciplinary group of Belgian experts in sequencing treatments for patients with mCRPC, with a focus on radium-223 dichloride.
(BELG J MED ONCOL 2019;13(6): 240–250)Read more
BJMO - 12, issue 3, february 2018
E. Seront MD, PhD
Multiple immune checkpoint inhibitors (ICIs) are currently available for the treatment of bladder cancer. The question raised by Dr Seront in his lecture was: “which agent should be used for which patient?”Read more
BJMO - volume 11, issue 9, february 2017
E. Seront MD, PhD, J.P. Machiels MD, PhD
Immunotherapy harnesses the immune system to recognize and destroy cancer cells. This review focuses on the different agents that are currently approved in genitourinary cancers and highlights promising therapeutic strategies in this field. The clinical data generated in advanced urological cancer, advanced renal cell carcinoma (RCC) and metastatic prostate cancer will be discussedRead more
BJMO - volume 10, issue 6, september 2016
T. Vermassen PhD, R. de Wit MD, PhD, R. van Velthoven MD, PhD, S. Albisinni MD, N. Martínez Chanzá MD, F. Aoun MD, MSc, E. Seront MD, PhD, S. Rottey MD, PhD
Due to the success of last year, a third national Belgian Multidisciplinary scientific meeting on Urological Cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisms involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J.P. Machiels, G. Pelgrims, S. Rottey (members of BSMO), L. Hoekx, S. Joniau, T. Roumeguere (members of BAU), O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO-BVRO). The third meeting, held in La Hulpe, Brussels on March 5th, 2016 was a great success with more than 100 attendees of the different specialisms involved.
In this report of the meeting you can find a summary of the most important lectures given at the symposium.
(BELG J MED ONCOL 2016;10(6):232–235)Read more